RESULTS: A total of 2486 clinic appointments were compiled for four providers in the adult urology clinic over six months. Of the total, 408 were actual missed clinic visits at an overall no-show rate of 16.4%. The calculated number of patients missing their appointments was 488. Of the predicted 488 missed visits, the calculated number of patients was over by 130 with an average of 1.19 patients over per day, and under by 50 with an average of 0.46 patients under per day. The number of perfect days where the predicted number matched the actual number was 26/109 (23.9%), within +/-1 patients 61/109 (56.0%), and within +/-2 patients 87/109 (79.8%). Conversely, the model over predicted 4 or greater patient no-shows on 6/109 (5.5%) of days. Overpredicted patients per day ranged from 0.01-6.5 with a mean of 1.58.
INTRODUCTION AND OBJECTIVES: The Urological Outcomes Data Base (UODB) has existed for 15 years and contains data on over 6,000 patients treated for prostate cancer at University of California, San Francisco (UCSF). Until recently, clinical data in UODB have been manually abstracted from patient records. We are now implementing automated data extraction from the EPIC electronic health record system. EPIC is supported by a research database that automatically extracts patient data. We aim to study a set of chosen variables and compare the types and degrees of miscorrelation between automated and manual data extraction, to see if manual data extraction can be minimized or eliminated.
METHODS: In early 2016 we developed a set of Smart Data Elements (SDEs) for urologic oncology, including SDEs for men with prostate cancer. These SDEs are populated automatically from the EPIC clinician interface during routine clinical documentation, using either SmartForms or SmartLists embedded within a dozen new standardized templates. SDEs are available immediately in EPIC's Clarity database, and can be populated in future documentation notes. We selected 15 core sample SDEs for validation against manually abstracted data in UODB for patients seen in 2016. Manually abstracted values were compared directly to SDEs values to assess match frequency.
RESULTS: The 15 SDEs encompassed a wide range of variables from diagnosis to pathologic staging, including clinical risk characteristics at diagnosis, biopsy Gleason score and surgical pathology findings. The median number of patients per variable was 37 (IQR 17-39). Median number of matches per variable was was 14% (IQR 5-37) with median match rate of 70.6% (IQR 35.7-97.4%). Detailed match rates are shown in the table.
CONCLUSIONS: Next steps include expanding validation rules across a larger set of variables and exploring the limitations of the match strategy. In some cases, data sources such as a computerized system may prove more accurate than manual entry. Working with the AUA Quality (AQUA) registry, we plan to transfer subsets of SDEs to the EPIC Foundation repository, allowing access to any EPIC center.
Automated data extraction can improve clinical workflow and streamline data collection within urologic oncology. METHODS: Using a multicenter electronic data warehouse, we retrospectively identified all patients from 2012-2015 with a new diagnosis of MH. Characteristics of those who did and did not complete a FUUA were compared. Severity of MH on FUUA was related and compared to severity on the initial sample. In patients who had a FUUA, regression modeling was used to determine the association of a positive FUUA with a diagnosis of bladder cancer, kidney cancer, and nephrolithiasis after adjusting for age, sex, and degree of MH on index UA. RESULTS: Of the 7,879 patients identified with MH, 4,270 (54.1%) had a FUUA at a median time of 71 days after initial UA. Patients who had a FUUA were older (57 vs 53, p<0.001), more commonly female (57% vs. 53%, p¼0.001), but had no differences among races (p¼0.45). Degree of MH on index UA did not relate to completion of a FUUA (p¼0.08). Most FUUA (65.8%) were negative and there was a weak correlation between degree of MH on initial UA and FUUA (rs¼0.19, p<0.001), (Figure 1 ). After adjusting for age, gender and severity of MH on index UA, positive FUUAs were associated with increased odds of being diagnosed with bladder cancer, kidney cancer, and nephrolithiasis compared to a negative FUUA (Table 1) . Any FUUA with 11 or more RBC/hpf increased the risk of bladder cancer diagnosis significantly over a negative FUUA. Conversely, in kidney cancer and urolithiasis, compared to a negative FUUA, only a FUUA with 100+ RBC/hpf increased the odds of diagnosis.
Source of
CONCLUSIONS: A positive FUUA may help to better identify patients with bladder cancer, kidney cancer, and urolithiasis-but only at severe thresholds of RBC/hpf.
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